title: Dose-related difference in progression rates of cytomegalovirus retinopathy during foscarnet maintenance therapy. AIDS Clinical Trials Group Protocol 915 Team.
abstract: OBJECTIVE
  A previous dose-ranging study of foscarnet maintenance therapy for cytomegalovirus retinopathy showed a positive relationship between dose and survival but could not confirm a relationship between dose and time to first progression. This retrospective analysis of data from that study was undertaken to determine whether there was a relationship between dose and progression rates, which reflects the amount of retina destroyed when progression occurs.
  
  
  METHODS
  Patients were randomly given one of two foscarnet maintenance therapy doses (90 mg/kg of body weight/day [FOS-90 group] or 120 mg/kg of body weight/day [FOS-120 group] after induction therapy. Using baseline and follow-up photographs and pre-established definitions and methodology in a masked analysis, posterior progression rates and foveal proximity rates for individual lesions, selected by prospectively defined criteria, were calculated in each patient. Rates were compared between groups.
  
  
  RESULTS
  The following median rates were greater for the FOS-90 group (N = 8) than for the FOS-120 group (N = 10): greatest maximum rate at which lesions enlarged in a posterior direction (43.5 vs 12.5 microns/day; P = .002); posterior progression rate for lesions closest to the fovea (42.8 vs 5.5 microns/day; P = .010); and maximum foveal proximity rate for either eye (32.3 vs 3.4 microns/day; P = .031).
  
  
  CONCLUSIONS
  Patients receiving higher doses of foscarnet have slower rates of progression and therefore less retinal tissue damage during maintenance therapy. A foscarnet maintenance therapy dose of 120 mg/kg of body weight/day instead of 90 mg/kg of body weight/day may help to preserve vision in patients with cytomegalovirus retinopathy.
authors.affiliation: UCLA Ocular Inflammatory Disease Center, Jules Stein Eye Institute 90024-7003, USA.
authors.forename: G N
authors.initials: GN
authors.lastname: Holland
authors.forename: R D
authors.initials: RD
authors.lastname: Levinson
authors.forename: M A
authors.initials: MA
authors.lastname: Jacobson
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000503:physiopathology; D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D000328:Adult; D017726:Cytomegalovirus Retinitis / Q000188:drug therapy* / Q000503:physiopathology*; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D017245:Foscarnet / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D012173:Retinitis / Q000188:drug therapy* / Q000503:physiopathology; D012189:Retrospective Studies
chemical_list: D017245:Foscarnet